According to a recent LinkedIn post from Benchling, the company has published results from BenchBench-Protocol, a benchmark designed to test how large language models perform in troubleshooting and optimizing wet lab protocols. The benchmark draws on thousands of real-world experiments and evaluates whether models can operate at the level of expert scientists in practical lab settings.
The post highlights that top-performing models in this benchmark include Opus 5, GPT 5.6, and Kimi K3, while emphasizing that current systems still struggle with practical details and judgment calls at the bench. Benchling indicates it is developing additional benchmarks focused on real scientific workflows, from sequence design to experimental planning, which may reinforce its positioning as a critical data and tooling provider for AI-enabled life science R&D.
For investors, this activity suggests Benchling is actively aligning its platform with the emerging intersection of biology and AI, potentially increasing its strategic value to pharma, biotech, and research institutions seeking validated AI tools. By owning and publishing domain-specific benchmarks, the company could strengthen its role in setting industry standards, support deeper integrations with leading model providers, and create future monetization opportunities around AI-driven lab productivity and decision-support solutions.